Hellow guys, Welcome to my website, and you are watching Novel Drug for Treatment of Type 2 Diabetes. and this vIdeo is uploaded by Cleveland Clinic at 2022-02-16T06:00:27-08:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | Novel Drug for Treatment of Type 2 Diabetes |
| Video Uploader | Video From Cleveland Clinic |
| Upload Date | This Video Uploaded At 16-02-2022 14:00:27 |
| Video Discription | To learn more about the top medical innovations for 2022, please visit https://cle.clinic/3GPe1c9 In the United States, 1 in 10 individuals has diabetes, which affects how the body processes food into energy. One potential therapy is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. Additionally, it slows digestion, resulting in individuals remaining full longer and eating less. Thus far, late phase III clinical trials reveal that the treatment significantly reduces hemoglobin A1C in type 2 diabetes and supports weight loss, making it potentially the most effective therapy for diabetes and obesity yet developed. ▶Share this video with others: https://youtu.be/kpXsJ8WyQI4 ▶Subscribe to learn more about Cleveland Clinic: https://www.youtube.com/user/ClevelandClinic?sub_confirmation=1 #ClevelandClinic #MedicalInnovations |
| Category | Science & Technology |
| Tags | medical innovations 2022 | cleveland clinic innovations | top 10 medical innovations | medical innovations from cleveland clinic | medical innovations | top 10 medical innovation 2022 | top 10 medical innovation cleveland clinic | 4219 | cleveland clinic | the top 10 most promising medical technologies | insulinotropic polypeptide (gip) | glucagon like peptide 1 | gip for type 2 diabetes | glp 1 diabetes | new type 2 diabetes medications | glp-1 and gip receptors |
